Building on an alliance dating back to 2016, Exscientia and Sanofi will use artificial intelligence and insights gleaned from patient tissue samples to seek out 15 novel therapies.

Major medtech deals in November include Coloplast's $2.5bn acquisition of Atos Medical and Alcon's deal for Ivantis.

New company licenses obicetrapib from Amgen after previous companies’ setbacks in CETP class and works with FDA on a Phase III protocol. BMS buys protein-engineering specialist Forbius.

Sanofi Pasteur’s dengue vaccine candidate became the first of its type to enter phase III with announcement by the company of a new clinical study in Australia, part of global phase III clinical study programme for the prevention of dengue disease in children and adults.